CapsoVision Reports Q3 2026 Results with Revenue Growth and Strengthened Balance Sheet
CapsoVision (CV) reported third-quarter 2026 revenue of $3.6 million, a 1% increase compared to the same period in 2025. While gross margins declined to 49% from 54% due to rising flash memory costs and a $250,000 inventory obsolescence charge, the company successfully reduced its net loss to $7.3 million ($0.15 per share) through disciplined expense management. The company achieved significant operational milestones, including the FDA clearance and subsequent commercial launch of its AI Highlights tool for CapsoCam Plus. Additionally, CapsoVision completed clinical enrollment for its second-generation CapsoCam Colon study and plans to submit for FDA approval by the end of 2026. A recent registered direct offering bolstered cash reserves to $21.8 million, providing a liquidity cushion for upcoming product launches.
Tickers: $CAPS
Topics: gross margin net loss operating expenses revenue growth shipments